GALVUS NOVARTIS PDF

Novartis’ Galvus (vildagliptin) is a member of a new class of oral antidiabetic agents known as dipeptidyl peptidase IV inhibitors (DPP-IV) inhibitors or ‘incretin . Galvus Approval Status. FDA Approved: No Brand name: Galvus Generic name: vildagliptin. Previous Name: LAF Company: Novartis Pharmaceuticals. Vildagliptin is an oral anti-hyperglycemic agent (anti-diabetic drug) of the dipeptidyl The European Medicines Agency has also approved a combination of vildagliptin and metformin, vildagliptin/metformin (Eucreas by Novartis) as an oral.

Author: Kagaktilar Kizil
Country: South Africa
Language: English (Spanish)
Genre: Travel
Published (Last): 22 November 2014
Pages: 91
PDF File Size: 14.30 Mb
ePub File Size: 16.41 Mb
ISBN: 526-3-22817-641-7
Downloads: 94697
Price: Free* [*Free Regsitration Required]
Uploader: Nashakar

Furazolidone Furazolidone may increase the hypoglycemic activities of Vildagliptin. Melitracen Melitracen may decrease the hypoglycemic activities of Vildagliptin. Bumetanide The therapeutic efficacy of Vildagliptin can be increased when used in combination with Bumetanide.

The therapeutic efficacy of Vildagliptin can gavlus increased when used in combination with Sulfadicramide.

Galvus 50 mg Tablets

Clinical studies performed with healthy subjects have shown no clinically relevant pharmacokinetic interactions. The therapeutic efficacy of Vildagliptin can be increased when used in combination with Sulfametopyrazine.

The risk or severity of hypoglycemia can be increased when Cinnarizine is combined with Vildagliptin. Clopamide The therapeutic efficacy of Vildagliptin can be increased when used in combination with Clopamide.

Venlafaxine The risk novaris severity of hypoglycemia can be increased when Venlafaxine is combined with Vildagliptin. Subscribe to free Drugs. Patients who develop increased transaminase levels should be monitored with a second liver function evaluation to confirm the finding and be followed thereafter with frequent liver function tests until the abnormality ies return s to normal. Ciclesonide The therapeutic efficacy of Vildagliptin can be decreased when used in combination with Ciclesonide.

  ESSENTIAL HISTOLOGY CORMACK PDF

Streptokinase The risk or severity of angioedema can be increased when Streptokinase is combined with Vildagliptin.

Cortivazol The therapeutic efficacy of Vildagliptin can be decreased when used in combination with Cortivazol. Dersalazine Dersalazine may increase the hypoglycemic activities of Vildagliptin. Epinephrine The therapeutic efficacy of Vildagliptin can be decreased when used in combination with Epinephrine.

At mg, there were three cases of muscle pain, and individual cases of mild and transient paraesthesia, fever, oedema and a transient increase in lipase levels.

Doses of vildagliptin above mg are not recommended.

Benzthiazide The therapeutic efficacy of Vildagliptin can be decreased when used in combination with Benzthiazide. Acetyl sulfisoxazole The therapeutic efficacy of Vildagliptin can be increased when used in combination with Acetyl sulfisoxazole. Fluticasone furoate The therapeutic efficacy of Vildagliptin can be decreased when used in combination with Fluticasone furoate. Olanzapine Novzrtis therapeutic efficacy of Vildagliptin can be decreased when used in combination with Olanzapine.

Pipemidic acid The therapeutic novatis of Vildagliptin can be increased when used in combination with Pipemidic acid. The therapeutic efficacy of Vildagliptin can be increased when used in combination with Meticrane.

Vildagliptin

The risk or severity of hypoglycemia can be increased when Glucagon recombinant is combined with Vildagliptin. Dexamethasone The therapeutic efficacy of Vildagliptin can be decreased when used in combination with Dexamethasone. Trandolapril The risk or severity of angioedema can be increased when Trandolapril is combined with Vildagliptin. The therapeutic efficacy of Vildagliptin can be decreased when used in combination with Lopinavir.

  COMPORTAMIENTO ORGANIZACIONAL POR DON HELLRIEGEL Y JOHN SLOCUM PDF

The known effect of increased GLP-1 levels delaying gastric emptying is not observed with vildagliptin treatment.

Vildagliptin – Wikipedia

nocartis The therapeutic efficacy of Vildagliptin can be decreased when used in combination with Sirolimus. The risk or severity of hypoglycemia can be increased when Vildagliptin is combined with Lobeglitazone. In clinical trials, the magnitude of HbA 1c reductions with vildagliptin was greater in patients with higher baseline HbA 1c.

The risk or severity of angioedema can be increased when Vildagliptin is combined with Saxagliptin. The incidence of noartis in the overall population was 4.

Insulin peglispro Vildagliptin may increase the hypoglycemic activities of Insulin peglispro. Torasemide The therapeutic efficacy of Vildagliptin gzlvus be increased when used in combination with Torasemide. In comparative controlled monotherapy studies, hypoglycaemia was uncommon, reported in 0. Pioglitazone The risk or severity of hypoglycemia can be increased when Pioglitazone is combined with Vildagliptin.